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Abstract
Introduction: Recombinant human soluble thrombomodulin (rhTM) is a novel anti-coagulant agent that regulates
the imbalanced coagulation system by reducing the excessive activation of thrombin. rhTM potentially reduces the
morbidity and mortality in patients with sepsis-induced disseminated intravascular coagulation (DIC). However, the
efficacy of rhTM in obstetric DIC has not yet been established. We performed this study to examine whether the
administration of rhTM was a potentially effective treatment for DIC induced by one or more underlying obstetric
disorders.
Methods: This is a single-center, retrospective cohort study conducted between January 2007 and February 2015
using the records of the Department of Obstetrics at the Perinatal Medical Center of TOYOTA Memorial Hospital,
Aichi, Japan. The eligibility criteria were known or suspected obstetric DIC documented on the basis of clinical and
laboratory data and association with one or more major underlying obstetric disorders. Baseline imbalance between
patients with and without treatment of rhTM was adjusted using an inverse probability of treatment weighting
using propensity scores composed of the following independent variables: severe postpartum hemorrhage,
placental abruption, and preeclampsia/eclampsia, including hemolysis, elevated liver enzymes, and low platelet
syndrome, initial platelet counts, D-dimer levels, fibrinogen levels, and prothrombin time–international normalized
ratio (PT–INR). We evaluated laboratory changes and clinical outcomes in the early phase of obstetric DIC.
Results: In total, 66 of 4627 patients admitted to our department during the study period fulfilled the required
criteria; of these, 37 and 29 patients were included in the rhTM and control group, respectively. After adjustment,
treatment with rhTM was associated with significant improvements in platelet counts, D-dimer levels, fibrinogen
levels, and PT–INR compared with the control group. The platelet concentrate transfusion volume was significantly
lower in the rhTM treatment group (3.02 vs 6.03 units, P = 0.016). None of the adjusted group differences were
statistically significant for all types of organ damage and failure.
Conclusion: rhTM administration was associated with clinical and laboratory improvement in patients with DIC
caused by underlying obstetric conditions. Further clinical research is needed to clarify the optimal application of
rhTM in each of the causative obstetric disorders.
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Introduction
Obstetric disorders are a major cause of disseminated
intravascular coagulation (DIC), which increases mater-
nal and fetal morbidity and mortality [1, 2]. In a study
based on the United States Nationwide Inpatient Sample
between 1998 and 2009, approximately one quarter of
maternal deaths were related to obstetric DIC [3]. The
most common obstetric complications associated with
DIC are severe postpartum hemorrhage, placental
abruption, and preeclampsia/eclampsia, including the
syndrome of hemolysis, elevated liver enzymes, and low
platelets (HELLP) [2]. In the management of DIC, the
goal is to remove the underlying condition and provide
intensive supportive care [1]. Although some drugs, such
as heparin, antithrombin concentrates, or gabexate mesi-
late, control coagulation in the treatment of DIC, their
efficacy remains uncertain [1, 4].
Recombinant human soluble thrombomodulin (rhTM)
is a novel anti-coagulant agent composed of the active,
extracellular domain of thrombomodulin (TM) that reg-
ulates the imbalanced coagulation system by reducing
excessive activation of thrombin [5]. Additionally,
rhTM has antifibrinolytic and anti-inflammatory prop-
erties, which are supposed to mitigate some of the
catastrophic conditions of DIC [6]. In Japan, it has
been reported that rhTM potentially reduces the mor-
bidity and mortality in patients with sepsis-induced
DIC [7–9]. Similarly, an international, randomized,
placebo-controlled, phase IIb clinical trial of rhTM in
patients with sepsis and suspected DIC [10] suggested
that this treatment is both efficacious and safe, stimu-
lating enthusiasm for the application of rhTM in crit-
ical care. On the other hand, the efficacy of rhTM in
obstetric DIC has not yet been established. One recent
study demonstrated the possible effectiveness of rhTM
in postpartum hemorrhage with DIC [11]. However,
obstetric DIC does not always comprise a single under-
lying disorder but often arises from multiple obstetric
complications, some of which overlap and interact
with each other. We performed this study to examine
whether administration of rhTM is a potentially effect-




We conducted a single-center, retrospective cohort
study between January 2007 and February 2015 using
the records of the Department of Obstetrics at the Peri-
natal Medical Center of TOYOTA Memorial Hospital,
Aichi, Japan. This study was approved by the ethical
committee of TOYOTA Memorial Hospital and was
conducted in accordance with the principles of the Dec-
laration of Helsinki. Because rhTM was approved for
DIC, including obstetric DIC and available for market
use in Japan, the committee did not require informed
consent for this retrospective study.
Patients who met the following criteria were eligible:
known or suspected obstetric DIC documented on the
basis of clinical and laboratory data and association with
one or more major underlying obstetric disorders, such
as postpartum hemorrhage (total blood loss over
1000 mL), placental abruption, and preeclampsia/
eclampsia, including HELLP syndrome. DIC was diag-
nosed using the DIC score of the Japanese Association
for Acute Medicine (JAAM) or the obstetric DIC score
approved by the Japanese Society of Obstetrics and
Gynecology (Table 1) [12, 13]. In all patients the criteria
for diagnosis of DIC were fulfilled by one or both of
these scores.
The exclusion criteria were as follows: the presence of
acute or chronic hepatic failure related to non-obstetric
causes; known congenital coagulopathy diagnosed before
pregnancy; underlying comorbidity, such as chronic
renal failure, untreated diabetes mellitus, and malig-
nancy, which could affect patient outcome; and missing
clinical or laboratory data.
Treatment
The management of patients with obstetric DIC focused
on identifying and treating the underlying disorders and
providing supportive care, which included mechanical
ventilation, vasoactive agents, and blood products. All
the patients underwent vaginal or cesarean delivery on
the day in which DIC was diagnosed as being induced
by an underlying obstetric disorder. In the patients with
postpartum hemorrhage, DIC was assessed after delivery,
while those with either placental abruption or pre-
eclampsia/eclampsia were diagnosed before delivery.
In the rhTM group, rhTM was administered at a dose
of 0.06 mg/kg/day via intermittent bolus over 30 minutes
at the discretion of the attending physician after asses-
sing the patient’s condition. The rhTM treatment was
only initiated after delivery because rhTM was contrain-
dicated for pregnant women, and it was discontinued
after the improvement of both clinical conditions and la-
boratory parameters.
Blood transfusions were performed principally ac-
cording to the management protocols for obstetric
hemorrhage [14]. One unit each of red blood cells
(RBCs), fresh frozen plasma (FFP), and platelet concen-
trate (PC) was equivalent to approximately 200 mL of
whole blood. Fibrinogen concentrates were also used
for the patients who required rapid replacement of co-
agulation factors. In some patients, protease inhibitors,
such as antithrombin concentrates, gabexate mesilate,
and nafamostat mesilate, were administered empirically.
Some patients admitted to the ICU were treated with
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vasoactive agents such as norepinephrine and vasopres-
sin or mechanical ventilation, as necessary.
Data collection
We collected data on baseline characteristics, including
the present obstetric status, associated underlying diag-
nosis, total postpartum hemorrhage volume, initial la-
boratory results, initial JAAM and obstetric DIC scores,
and therapeutic interventions provided. The following
outcome measures were recorded on the day in which
the patient was diagnosed with obstetric DIC and ap-
proximately two days after diagnosis: platelet counts, D-
dimer levels, fibrinogen levels, and prothrombin time–
international normalized ratio (PT–INR). Within 4 days
after the diagnosis of obstetric DIC, we also compiled
data for the occurrences of bleeding events and DIC-
related organ damage and failure (heart, lung, kidney,
and liver) as well as for the number of units transfused
of RBC, FFP, PC, and fibrinogen concentrates. We
defined organ damage and failure as follows; heart,
decreased ejection fraction (<50 %), or increased E/E’
(>8.0) with elevated serum brain natriuretic peptide level
(>200 pg/mL); respiratory, fulfilling the criteria of acute
respiratory distress syndrome, or requiring mechanical
ventilation; renal, fulfilling the criteria of acute kidney
injury; liver, increased serum liver enzyme levels (as-
partate aminotransferase or alanine aminotransferase
greater than three times the upper limit of normal).
Statistical analysis
To assess the effect of the novel anticoagulant in this
non-randomized experiment, we used a propensity score
(PS) method in which the scores were estimated by




Stiffening of the uterus, death of the fetus 5
Stiffening of the uterus, survival of the fetus 4
Confirmatory diagnosis of placental abruption by
ultrasonic tomographic findings and CTG findings
4
b. Amniotic fluid embolism
Acute cor pulmonale 4
Artificial ventilation 3
Assisted respiration 2
Oxygen flux alone 1
c. DIC-type postpartum hemorrhage
In case the blood from the uterus has low coagulability 4
Hemorrhage of >2000 mL (within 24 hours after the
start of hemorrhage)
3
Hemorrhage of 1000–2000 mL (within 24 hours after





Those with fever accompanied by shock, bacteremia,
and endotoxemia
4
Continued fever or remittent fever 1
f. Other underlying diseases 1
2. Clinical symptoms
a. Acute renal failure
Anuria (<5 mL/hour) 4
Oliguria (5–20 mL/hour) 3
b. Acute respiratory failure (amniotic fluid embolism
excluded)
Artificial ventilation or occational assisted respiration 4
Oxygen flux alone I
c. Organ failure
Heart (rales or foamy sputum, etc.) 4
Liver (visible jaundice, etc.) 4
Brain (clouding of consciousness, convulsion, etc.) 4
Digestive tract (necrotic enteritis, etc.) 4
Other severe organ failure 4
d. Hemorrhage diathesis
Macroscopic hematuria and melena, purpura, etc. 4
e. Shock symptoms
Pulse rate ≥100/minute 1
Blood pressure ≤90 mm Hg (systolic) or reduction ≥40 % 1
Cold sweat 1
Pallor 1
Table 1 Obstetric DIC score (Continued)
3. Laboratory findings
Serum FDP ≥10 pg/mL 1
Platelet counts ≤100 × 109/L 1
Fibrinogen ≤150 mg/dL 1
PT ≥15 seconds (≤50 %) or hepaplastin test ≤ 50 % 1
Erythrocyte sedimentation rate of ≤4 mm/15 minutes
or ≤15 mm/hour
1
Bleeding time ≥5 minutes 1
Other coagulation and fibrinolysis factors;
antithrombin ≤18 mg/dL or ≤60 %, plasminogen,







DIC disseminated intravascular coagulation, CTG cardiotocography, FDP fibrin/
fibrinogen degradation products, PT prothrombin time
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fitting a multivariate logistic regression model to the ori-
ginal population of treated and untreated patients [15].
The independent variables that seemed to be strongly
associated with the administration of rhTM were consid-
ered clinically and statistically relevant. Because of the
specific characteristics of obstetric DIC and the small
sample size of the retrospective cohorts, we included the
following independent variables: severe postpartum
hemorrhage, placental abruption, and preeclampsia/
eclampsia, including HELLP syndrome, initial platelet
counts, D-dimer levels, fibrinogen levels, and PT–
INR. We adjusted the cohorts for the probability of
treatment with the inverse probability weighting of
treatment (IPTW) approach. Each individual was
weighted by the inverse probability of receiving the
treatment, equal to 1/PS for treated individuals or
1/(1− PS) for control individuals. With the IPTW
method, no loss of sample occurs as that associated
with alternative methods such as PS matching; there-
fore, this was considered beneficial for this small
observational study [16, 17]. The standardized differ-
ences [18] of the independent variables before and
after adjustment were calculated to evaluate the bal-
ances of these variables and the effectiveness of the
PS-based IPTW analysis.
Comparisons between the groups were analyzed by
Student’s t test or the Mann–Whitney U test for con-
tinuous variables as appropriate and by the chi-square
or Fisher’s exact test for categorical variables. The
changes in laboratory parameters from the baseline
levels in the adjusted cohorts were analyzed by re-
peated measures analysis of variance adjusted for the
baseline data as a covariate and by the post hoc Bon-
ferroni test. The degrees of freedom were corrected
using Greenhouse–Geisser estimates of sphericity.
Homogeneity of variances was also examined with
Levene’s test and the all parameters met the assump-
tion. The differences in total transfusion volumes
(RBC, FFP, PC, and fibrinogen concentrates) between
the groups were assessed by the Kruskal–Wallis test
before and after adjustment with the PS-based IPTW
analysis. The effectiveness of rhTM for secondary
organ damage and failure was also described as non-
adjusted, and the IPTW-adjusted odds ratios (ORs)
were estimated by logistic regression. Statistical sig-
nificance was determined two-sided with P <0.05. All
statistical analyses were carried out using IBM SPSS
Statistics for Windows, Version 22.0 (IBM Corp.,
Armonk, NY, USA).
Results
Baseline characteristics of patients
In total, 66 out of 4627 patients admitted to our de-
partment during the study period fulfilled the required
criteria; of these, 37 and 29 patients were included in
the rhTM group and the control group, respectively.
The baseline characteristics of the two groups were
comparable (Table 2). There were no differences in ob-
stetric history, delivery method, or underlying obstetric dis-
orders between the two groups. The total amount of
hemorrhage, initial laboratory results, JAAM DIC scores,
and obstetric DIC scores were also comparable; however,
the hemoglobin level differed (P = 0.013). For therapeutic
intervention, the rates of ICU admission and protease in-
hibitor administration were not different between the two
groups.
PS-based approach
PS was estimated for each individual by multivariate lo-
gistic regression modeling with the seven predetermined
independent variables. The P value for the Hosmer–
Lemeshow test of the PS model was 0.953, and that for
the c statistic was 0.740. Using the IPTW approach,
pseudo-populations were added for each group by
weighting cases. Standardized differences, imbalances of
independent variables between non-adjusted and ad-
justed cohorts, were reduced (Table 3). We also ob-
served the balance of baseline characteristics of
covariates within deciles of PS.
Laboratory parameters
Compared with the control group, platelet counts in the
rhTM group were significantly increased from the base-
line value at the post-treatment state approximately
2 days after the diagnosis (Fig. 1a). In terms of the co-
agulation parameters, D-dimer levels, fibrinogen levels,
and PT–INR were significantly improved after the initi-
ation of rhTM when compared with the control group
(Fig. 1b, c, d). The effect of the treatment over time
(from baseline to day 2) was also statistically significant
for all four parameters.
Blood transfusion
The total volumes of blood transfused within 4 days
of diagnosis with DIC are presented in Table 4. In
the original cohorts, there were no significant volume
differences of the components of blood transfused be-
tween the two groups. However, when compared with
the adjusted control group, the PC transfusion vol-
ume was significantly lower in the adjusted rhTM
group (3.02 vs 6.03 units, P = 0.016). The other blood
components were transfused at similar volumes
among patients in the adjusted groups.
Organ damage and failure related to DIC
DIC-related acute organ damage and failure was ob-
served in some patients within 4 days after the onset of
obstetric DIC (Table 5). In the original cohorts, liver
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damage was significantly less frequent in the rhTM
group than in the control group (OR, 0.180; 95 % confi-
dence interval, 0.034–0.944; P = 0.043). After adjust-
ment, none of the group differences were statistically
significant for any type of organ damage or failure.
Adverse events
Three patients presented with a puerperal hematoma
after vaginal delivery and treatment for massive postpar-
tum hemorrhage, of which two occurred after rhTM ad-
ministration. No other bleeding-related adverse events
or death occurred during the study period.
Discussion
In the present study, rhTM was associated with signifi-
cant improvements in platelet counts, D-dimer levels, fi-
brinogen levels, and PT–INR when compared with those
associated with the control group. The decreased PC
transfusion volume also indicates the potential efficacy
of rhTM in obstetric DIC. Specifically, by decreasing the
imbalances between the two groups, the PS-based IPTW
analysis enabled us to clarify this therapeutic effect. To
our knowledge, this is the first retrospective cohort
study to provide evidence of the potential efficacy of
rhTM in DIC caused by underlying obstetric disorders.
Table 3 Standardized differences of the independent variables
Standardized difference
Non-adjusted Adjusted
Severe postpartum hemorrhage 0.425 −0.020
Placental abruption 0.041 0.040
Preeclampsia/eclampsia/HELLP syndrome −0.345 0.040




HELLP hemolysis, elevated liver enzymes, and low platelets, PTxINR prothrombin
time–international normalized ratio
Table 2 Baseline characteristics of the patients
rhTM group Control group P valuea
(n = 37) (n = 29)
Age, years, mean (SD) 33.0 (4.8) 31.8 (5.1) 0.326
Nulliparous, n (%) 20 (54.1) 16(55.1) 1.000
Twin pregnancy, n (%) 4 (10.8) 2 (6.9) 0.668
Delivery method, n (%)
Normal vaginal delivery 10 (27.0) 7 (24.1) 1.000
Vacuum extraction/Forceps delivery 9 (24.3) 6 (20.7) 0.775
Cesarean section 18 (48.6) 16 (55.2) 0.628
Diagnosis, n (%)
Severe postpartum hemorrhageb 31 (83.7) 19 (65.5) 0.147
Placental abruptionb 16 (43.2) 12 (41.4) 1.000
Preeclampsia/eclampsia/HELLP syndromeb 7 (18.9) 10 (34.5) 0.169
Total hemorrhage volume, mL mean (SD) 2164.5 (1193.3) 1795.8 (1212.3) 0.221
Laboratory parameters, mean (SD)
White blood count, × 103/μL 16.75 (5.61) 16.63 (6.02) 0.937
Hemoglobin, g/dL 7.11 (2,00) 8.59 (2.70) 0.013
Platelet count, × 109/Lb 104.5 (51.9) 123.4 (71.8) 0.219
D-dimer, μg/mLb 116.3 (165.9) 116.6 (244.5) 0.995
Fibrinogen, mg/dLb 175.0 (94.4) 234.4 (138.4) 0.051
PT-INRb 1.346 (0.491) 1.426 (0.706) 0.587
JAAM DIC score, median (IR) 4.0 (3.0–6.0) 5.0 (2.0–7.0) 0.937
Obstetric DIC score, median (IR) 11.0 (9.0–14.0) 10.0 (8.0–13.0) 0.296
Theraputic intervention, n (%)
ICU admission 10 (27.0) 8 (27.6) 1.000
Protease inhibitor 16 (43.2) 17 (58.6) 0.321
Data are expressed as group mean (SD), median (interquartile range (IR)), or proportion (%). aP value between the two groups from analysis using Student’s t–test
or Mann–Whitney U test for continuous variables as appropriate, and by chi-square or Fisher’s exact test for categorical variables. bThe seven independent variables
used in propensity score calculation. rhTM recombinant human soluble thrombomodulin, HELLP hemolysis, elevated liver enzymes, and low platelets, PT–INR prothrom-
bin time–international normalized ratio, JAAM Japanese Association for Acute Medicine, ICU intensive care unit
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The anticoagulant efficacy of rhTM has been described
in DIC caused by the uncontrolled and excessive pro-
duction of thrombin, leading to widespread and systemic
intravascular fibrin deposition [1]. In vitro studies have
shown that TM directly or indirectly inhibits further
thrombin generation and inactivates the cleavage of
fibrinogen and subsequent microvascular thrombus
formation [19, 20]. The competitive inhibition of rhTM,
which decreases the interaction between thrombin and
fibrinogen, can directly decrease fibrinogen-to-fibrin
degradation. Moreover, the relationship between throm-
bin and TM is reversible and much faster than that be-
tween thrombin and antithrombin, one of the most
important natural anticoagulants [21]. This suggests that
rhTM can exert its anticoagulant effects by reducing the
speed of thrombin and antithrombin reaction, but without
losing the core function of antithrombin. In addition,
thrombin–rhTM complexes enhance protein C to gener-
ate activated protein C (APC), which serves as a negative
regulator of the coagulation cascade through the inactiva-
tion of the cofactors Va and VIIIa [5]. In this study, we
found significant improvements in platelet counts and co-
agulation parameters from the baseline values after treat-
ment with rhTM, despite the same or lower requirement
of blood transfusion. Given the evidence base, this sug-
gests that rhTM suppressed the excessive consumption of
platelets and coagulation factors. Therefore, each of the
anticoagulant effects of rhTM appeared to act cohesively
to improve the procoagulant state observed in DIC in-
duced by obstetric underlying disorders.
Fig. 1 Changes in key laboratory parameters from baseline in platelet counts (a), D-dimer levels (b), fibrinogen levels (c), and PT–INR (d). Data are
described as group mean ± standard error of the mean. The effect of treatment over time was also statistically significant in all the four parameters:
*P <0.05 compared with the control group; †P <0.05 compared with baseline. rhTM recombinant human soluble thrombomodulin, PT–INR prothrombin
time–international normalized ratio
Table 4 Total transfusion amounts received by patients
rhTM group Control group P valuea
(n = 37) (n = 28)
RBC, units, mean (median)
Non-adjusted 5.65 (4.00) 4.83 (2.00) 0.164
Adjusted 4.90 (4.00) 5.62 (4.00) 0.876
FFP, units, mean (median)
Non-adjusted 7.73 (5.00) 5.93 (5.00) 0.360
Adjusted 7.02 (5.00) 6.65 (5.00) 0.537
PC, units, mean (median)
Non-adjusted 3.11 (0.00) 6.21 (0.00) 0.098
Adjusted 3.02 (0.00) 6.03 (0.00) 0.016
Fibrinogen, g, mean (median)
Non-adjusted 0.32 (0.00) 0.17 (0.00) 0.822
Adjusted 0.49 (0.00) 0.22 (0.00) 0.706
Data are expressed as group mean (median). aP value between the two groups
in the Kruskal–Wallis test. RBC red blood cells, FFP fresh frozen plasma, PC
platelet concentrate
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TM binding to thrombin is also known to have antifi-
brinolytic efficacy by enhancing thrombin activatable fi-
brinolysis inhibitor (TAFI), the precursor of a basic
carboxypeptidase (TAFIa), thereby stabilizing fibrin
clots and ensuring localization to the sites of vascular
injury. Fibrinolysis originates from the binding of plas-
minogen and tissue-plasminogen activator to the fibrin
surface through the recognition of C-terminal lysine,
the cleavage of which is induced by TAFIa [20, 22]. This
can mediate the relatively profibrinolytic status arising
from consumption coagulopathy, but without provoking
hemorrhagic complications. During the peripartum
period, bleeding sites are inevitably formed by injury to
the parturient canal or by cesarean section. Besides, ob-
stetric hemorrhage can be aggravated by bleeding diath-
esis in DIC [2]. In such a prohemorrhagic environment,
rhTM does not appear to deteriorate the vicious profi-
brinolytic cycle induced by the activation of TAFI. How-
ever, this assumes that plasma replacement therapy is
appropriately performed for the associated consump-
tion coagulopathy, as demonstrated in our study.
In addition to its anticoagulant and antifibrinolytic ef-
fects, TM has anti-inflammatory properties, differentiat-
ing rhTM from other anticoagulants [19, 20]. TM binds
to thrombin and mediates its proinflammatory activities
to induce various chemical mediators. APC, enhanced
by the TM–thrombin complex then independently in-
hibits the expression of several cytokines, resulting in in-
flammation being suppressed [19, 20, 23]. Under DIC
conditions, excessive activation of coagulation yields
proteases that influence systemic inflammation and pro-
duce extensive endothelial damage and multiple organ
failure [1]. Therefore, in addition to the prompt elimin-
ation of the causes and of the ongoing thrombin gener-
ation, the administration of rhTM in the early phase of
DIC seems to be able to minimize systemic inflamma-
tion and reduce secondary organ damage. In our analysis
of the adjusted cohorts, none of the group differences
were statistically significant for any type of organ dam-
age or failure. Further trials are needed to determine the
efficacy of rhTM for each type of organ damage and
organ failure.
In each obstetric underlying disorder, rhTM can demon-
strate its therapeutic effects with the following properties:
severe postpartum hemorrhage, one of the most common
causes of obstetric DIC, is associated with endothelial dys-
function caused by hypoxemia and metabolic acidosis.
This, in turn, induces excessive tissue factor production
and ultimately, consumption coagulopathy [2]. Although
plasma replacement therapy is indispensable for the
deficiency of coagulation factors, rhTM can prevent the
progression of DIC by providing anticoagulant, antifibrino-
lytic, and anti-inflammatory effects. Placental abruption is
another significant cause of obstetric DIC that is associated
with increased maternal and fetal morbidity and mortality
[2]. Herein, thrombin also plays a key role in the pathogen-
esis of the disease in the following manner: decidual bleed-
ing and hypoxia induce the release of tissue factor, which
generates abundant thrombin [24, 25]; this then leads to
the expression of inflammatory cytokines and excess co-
agulation that overwhelms hemostatic control mecha-
nisms, resulting in DIC [26]. It is prudent to initiate rhTM
immediately after delivery and the control of bleeding as in
case of severe postpartum hemorrhage. Preeclampsia is a
pregnancy-specific multisystem disorder that is also a
major cause of DIC in obstetrics [27]. The pathophysiology
of preeclampsia is still uncertain, but some observational
studies have reported that placental underperfusion, hyp-
oxia, and ischemia induce circulating antiangiogenic
factors that create widespread maternal endothelial dys-
function, resulting in hypertension and proteinuria [28].
The progression of endothelial dysfunction can also trigger
DIC via the release of proinflammatory cytokines and via
the activation of extrinsic coagulation pathways [2].
Eclampsia and the HELLP syndrome are considered the
most severe subtypes of preeclampsia, which can cause
critical brain and liver dysfunction and other severe mater-
nal and fetal sequelae [29]. In combination with the
termination of pregnancy, rhTM can biochemically medi-
ate the associated endothelial dysfunction through its anti-
coagulant and anti-inflammatory properties.
Although there might also be some concern about
the increased risk of bleeding, the critical concentra-
tion at which bleeding occurs is much higher than the
recommended dose, and there has been no clinical evi-
dence of a definite, direct interaction between rhTM
administration and increased risk of bleeding-related
complications in obstetric DIC [30]. In this study, a
Table 5 Comparison of organ damage and failure related to DIC among the original and adjusted cohorts
rhTM group Control group Original cohorts Adjusted cohorts
(n = 37) (n = 29) Odds ratio (95 % CI)a P valuea Odds ratio (95 % CI)a P valuea
Cardiac, n (%) 1 (2.7) 1 (3.4) 0.778 (0.047–12.990) 0.861 0.970 (0.114–8.283) 0.978
Respiratory, n (%) 3 (8.1) 2 (6.9) 1.191 (0.186–7.645) 0.854 0.409 (0.115–1.460) 0.186
Renal, n (%) 3 (8.1) 3 (10.3) 0.765 (0.143–4.102) 0.754 0.737 (0.219–2.474) 0.621
Liver, n (%) 2 (5.4) 7 (24.1) 0.180 (0.034–0.944) 0.043 0.587 (0.216–1.595) 0.296
aOdds ratio and P value estimated by logistic regression analysis. DIC disseminated intravascular coagulation, rhTM recombinant human soluble thrombomodulin
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puerperal hematoma was a reported bleeding-related
adverse event in three patients (two patients in the
rhTM group and one patient in the control group), but
it is uncertain whether this was because of the adminis-
tration of rhTM or DIC itself. Additionally, it is import-
ant to remember that treatment with rhTM should be
discontinued after confirming the improvement of clin-
ical and laboratory variables such as vital signs, platelet
counts, and coagulation parameters.
The limitations of this study include the lack of uni-
versal applicability of the obstetric DIC score and the ex-
istence of confounding factors between the groups
because of the retrospective study design. Although we
introduced a PS-based analysis to reduce the imbalance
between the original cohorts in the probability of the
rhTM treatment, some unknown confounding factors
may have been missed. Due to the difficulty of extrapo-
lating this retrospective analysis directly to any recom-
mendations for treatment, the results of this pilot study
should be the basis for additional studies, including ran-
domized trials to examine the efficacy and safety of
rhTM for obstetric DIC.
Conclusions
In conclusion, rhTM administration was associated with
clinical and laboratory improvement in patients with
DIC caused by underlying obstetric conditions. Further
clinical research is needed to clarify the optimal applica-
tion of rhTM in each of the causative obstetric disorders,
preferably in a multicenter, prospective cohort study, or
randomized trials with sufficient power to confirm the
results of this study.
Key messages
 To our knowledge, this is the first retrospective
cohort study to provide evidence of the efficacy of
rhTM in DIC caused by underlying obstetric disorders
 When compared with the control group, treatment
with rhTM was associated with significant
improvements in platelet counts, D-dimer levels,
fibrinogen levels, and PT–INR
 The decreased PC transfusion volume also indicates
the potential efficacy of rhTM in obstetric DIC
 None of the adjusted group differences were
statistically significant for any type of organ damage
or organ failure
 By decreasing the imbalances between the
two groups, the PS-based IPTW analysis
enabled us to clarify the therapeutic effects.
However, a multicenter prospective cohort study is
needed to clarify the optimal application of rhTM
in each obstetric disorder and to confirm the
results of this study
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